Cincinnati Children's Hospital Medical Center Logo

University of Cincinnati Department of Pediatrics

Loading...

Christopher Karp, MD

Title

Gunnar Esiason/Cincinnati Bell Chair

Director, Division of Molecular Immunology

Director, Cystic Fibrosis Research Center

Appointment

Professor of Pediatrics, University of Cincinnati College of Medicine

Email

chris.karp@cchmc.org

Phone

513-636-7608

Fax

513-636-5355

Credentials

BA: summa cum laude, with high honors in Philosophy, Brandeis University, Waltham, MA, 1978

MD: University of North Carolina School of Medicine, Chapel Hill, NC, 1986

Internal Medicine: Rhode Island Hospital, Brown University, 1986-1987.

Internal Medicine: Georgetown University Hospital, Georgetown University, 1987-1989.

NRSA Fellow: Laboratory of Parasitic Diseases, NIAID, 1989-1992.

Fellow in Infectious Diseases: Johns Hopkins University School of Medicine, 1992-1993.

Diplomate of the National Board of Medical Examiners, 1987

Diplomate in Internal Medicine, American Board of Internal Medicine, 1989

Diplomate in Infectious Disease, American Board of Internal Medicine, 1994

Certificate of Knowledge in Tropical Medicine and Travelers' Health, ASTMH, 1995

Awards and Honors

  • Council, Society for Leukocyte Biology, 2007-current
  • Chair, Program Committee, International Endotoxin and Innate Immunity Society, 2006
  • Gunnar Esisason/Cincinnati Bell Professorship, 2005
  • Chair, Program Committee, Infectious Diseases Society of America, 2004
  • Member, American Society of Clinical Investigation, 2003
  • Faculty of 1000, 2002
  • Fellow of the Infectious Diseases Society of America, 1999
  • Sandoz Clinician Scientist Award, Johns Hopkins University, 1994
  • NRSA Award (individual), NIAID, 1989-92
  • Medical School Merit Award, University of North Carolina, 1985
  • John Motley Morehead Fellow in Medicine, University of North Carolina, 1982-86
  • High honors in philosophy, Brandeis University, 1978
  • Summa cum laude, Brandeis University, 1978
  • Phi Beta Kappa, Brandeis University, 1978

Research

The Karp lab focuses on understanding the molecular mechanisms underlying regulation and dysregulation of inflammatory responses in human infectious, autoimmune and genetic diseases. Interrelated, ongoing areas of study include:

  1. The molecular mechanisms underlying dysregulation of pulmonary inflammatory responses in cystic fibrosis;
  2. Modifier genes for cystic fibrosis lung disease;
  3. Mechanisms of inflammation resolution: lipoxin and resolvin biology;
  4. Immune counter-regulation in leishmaniasis;
  5. In vivo regulation of IL-10 production;
  6. Biology and control of Toll-like receptor-driven signaling pathways in health and disease.

Lab Members

  • Leah Flick, BA, Lab Manager
  • Aurelien Trompette, BA, Research Assistant
  • Jamie Warning, Research Assistant
  • Jaclyn McAlees, PhD, Post-doctoral Fellow
  • Jessica Allen, PhD Candidate
  • Senad Divanovic, PhD; Post-Doctoral Fellow
  • Isaac Harley, MD, PhD Candidate
  • Nicholas Boespflug, MD, PhD Candidate
  • Stephanie Walters, PhD Candidate

Research Grants and Contracts

Lipid mediators and dysregulated inflammation in CF.  National Institutes of Health. April 2005 - February 2010. #R01HL079312.

The role of aeroallergen mimics of TLR complex proteins in asthma pathogenesis. American Asthma Foundation. July 2006- June 2010.

Regulation of TLR signaling and innate immunity by RP105. National Istitutes of Health, National Insitute of Allergy and Infectious Diseases. July 2007 - June 2012. #R01AI075159.

CFF-RDP development grant, component II. Cystic Fibrosis Foundation. August 2007- July 2012.

Novel Immune-based therapy for Leishmaniasis and TB. National Institutes of Health- National Institute of Allergy and Infectious Diseases. July 2009- June 2010. #R41AI082812.

Immunobiology of IFRD1, a gene modifying CF lung disease. National Institutes of Health; National Heart, Lung and Blood Insitute. August 2009- July 2013. #R01HL094576.

Publications, Most Recent

Wills-Karp M, Nathan A, Page K, Karp CL. New insights into the molecular mechanisms underlying allergenicity. Mucosal Immunology, Dec, 2009. (e-pub ahead of print).

Lykens J, Terrell C, Zoller E, Divanovic S, Trompette A, Karp CL, Aliberti J, Flick M, Jordan MJ. Macrophage and dendritic cell specific effects of IFN-g are revealed in vivo by mice expressing a dominant negative mutant IFN-g receptor in macrophage lineage cells. J Immunology. Dec, 2009. (e-pub ahead of print).

Pasternak BA, D'Mello S, Jurickova II, Han X, Wilson T, Flick L, Petiniot L, Uozumi N, Divanovic S, Traurnicht A, Bonkowski E, Kugathasan S, Karp CL, Denson LA. Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn¹s disease and murine colitis.Inflammatory Bowel Diseases. Nov, 2009. (e-pub ahead of print).

Perona-Wright G, Mohrs K, Szaba FM, Kummer LW, Madan R, Karp CL, Johnson LL, Smiley ST, Mohrs M. Systemic but not local infections elicit immunosuppresive IL-10 by natural killer cells. Cell Host Microbe. 2009; 6:503-512.

Murai M, Turovskaya O, Kim G, Madan R, Karp CL, Cheroutre H, Kronenberg M. IL-10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis.Nature Immunology. 2009. Published online 27 September 2009; doi:10.1038/ni.1791.

Sun J, Madan R, Karp CL, Braciale TJ. Effector T Cells Control Lung Inflammatio During Acute Influenza Virus Infection by Producing IL-10.Nature Medicine. 2009; 15: 277-84.

Pot C, Jin H, Awasthi A, Liu SM, Lai CY, Madan R, Sharpe AH , Karp CL, Miaw SC, Ho IC, Kuchroo VK. Cutting Edge: IL-27 Induces the Transcription Factor c-Maf, Cytokine IL-21, and the Contimulatory Receptor ICOS that Coordinately Act Together to Promote Differentiation of IL-10 Producing Tr1 Cells. J Immunology: 2009; 183: 797-80.

Madan, R, Demirick F, Divanovic S, Trompette A, Allen J, Gu Y, Khoudon M, Hildeman D, Cardin R, Finkelman F, Mohrs M, Mueller W, Roers A, Waisman A, Karp CL. Non-Redundant Counter-regularoty Roles for B Cell-Derived IL-10. J Immunology: 2009; 183:2312-20.

Tschöp MH, Hugenholtz P, and Karp CL. Getting to the Core of the Gut Microbiome.Nature Biotechnology; 2009: 27 344-46.

Gu YY, Harley ITW, Henderson LB, Aronow BJ, Vietor I, Huber LA, Harley JB, Kilpatrick JR, Langefeld CD, Williams AH, Jegga AG, Chen J, Wills-Karp M, Arshad SH, Ewart SL, Thio CL, Flick LM, Filippi MD, Grimes HL, Drumm ML, Cutting GR, Knowles MR, Karp CL. Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease.Nature Advanced Online Publication 2/25/09. 10.1038/nature07811. 2009.

Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10.Nature Medicine Advanced Online Publication 2/22/09. 10.1038/nm.1929. 2009.

Trompette A, Divanovic S, Visintin A, Madan R, Blanchard C, Hegde RS, Wills-Karp M, Gioannini TL, Weiss JP, Karp CL. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein, MD-2.Nature 2008;457:585-8.

Nebert DW, Karp CL. Endogenous functions of the Aryl hydrocarbon receptor: Intersection of cytochrome P450 (CYP1)-metabolized eicosanoids and AHR biology.J Biol Chem 2008;283:36061-5.

Dragin N, Shi Z, Madan R, Karp CL, Sartor MA, Chen C, Gonzalez FJ, Nebert DW. Phenotype of the Cyp1a1/1a2/1b1(-/-) triple knockout mouse.Molecular Pharmacology 2008;73(6):1844-56.

Byrnes AA, Li D, Park K, Thompson D, Mocilnikar C, Mohan P, Molleston JP, Narkewicz M, Zhou H, Wolf SF, Schwarz, Karp CL. Modulation of the IL-12/IFN-gamma axis by IFN-alpha therapy for hepatitis C. J Leukocyte Biol 2007;81(3):825-34.

Auwaerter PG, Karp CL. Coinfection with HIV and tropical infectious diseases I: Protozoal pathogens.Clin Infect Dis 2007;45(9):1208-14.

Auwaerter PG, Karp CL. Coinfection with HIV and tropical infectious diseases II: Helminthic, fungal, bacterial and viral pathogens.Clin Infect Dis 2007;45(9):1214-20.

Reckling S, Divanovic S, Karp CL, Wojciechowski S, Belkaid Y, Hildeman D. Pro-apoptotic Bcl-2 family member Bim promotes persistent infection and limits protective immunity.Infect Immunity 2008;76(3):1179-85.

Karp CL. Book Review: The strangest song: One father’s quest to help his daughter find her voice. J Clin Invest 2007;117(5):1117.

Karp CL, Colebunders R. Approach to the patient with HIV and coinfecting tropical infectious diseases. in Tropical Infectious Diseases: Principles, Pathogens, and Practice, 2ND Edition; ed. Guerrant RL, Walker DH, and Weller PF. Elsevier Churchill Livingstone, Philadelphia. 2006. 1642-84.

Divanovic C, Trompette A, Petiniot LK, Allen JA, Flick LM, Belkaid Y, Madan R, Haky JJ Karp CL. Regulation of TLR4 Signaling and the Host Interface with Pathogens and Danger: The Role of RP105.J Leukocyte Biol 2007;82(2):265-71.

Byrnes AA, Li DY, Park K, Thompson D, Mocilnikar C, Mohan P, Molleston JP, Narkewicz M, Zhou H, Wolf SF, Schwarz KB, Karp CL. (2006) Modulation of the IL-12/IFN-{gamma} axis by IFN-{alpha} therapy for hepatitis C.J Leukoc Biol.

Tripathi P, Madan R, Chougnet C, Divanovic S, Ma X, Wahl LM, Gajewski T, Karp CL, Hildeman DA. (2006) An adenoviral vector for probing promoter activity in primary immune cells.J Immunol Methods 311:19-30.

Divanovic S, Trompette A, Atabani SF, Madan R, Reckling S, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nature Immunol 2005 ; 6:571-8. Apr 24; [Epub ahead of print], PMCID: PMC2144914

Karp CL, Flick LM, Park KW, Softic S, Greer TM, Keledjian R, Uddin J, Yang R, Guggino WB, Atabani SF, Belkaid Y, Xu Y, Whitsett JA, Accurso FJ, Wills-Karp M, Petasis NA. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.Nature Immunol 2004; 5:388-392.

Wills-Karp M. Karp CL. Chitin checking: Novel insights into asthma.N Engl J Med 2004; 351:1455-57.

Wills-Karp M. Karp CL. Eosinophils in asthma: Remodeling a tangled tale. Science 2004; 305:1726-1729.

Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic disease: the hygiene hypothesis revisited. Nature Res Immunol 2001; 1:69-75.

Karp CL, Grupe A, Schadt E, Ewart SL, Keane-Moore M, Cuomo PJ, Köhl J, Wahl L, Kuperman D, Germer S, Aud D, Peltz G, Wills-Karp M. Identification of C5 as a susceptibility locus for experimental allergic asthma. Nature Immunol 2000; 1:221-226.

Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, DD Donaldson. Interleukin-13: Central mediator of allergic asthma. Science 1998;282:2258-2261.

 Karp CL, Wysocka M, Wahl LM, Cuomo PJ, B. Sherry, Ahearn JA, Trinchieri G, Griffin DE. Mechanism of suppression of cell-mediated immunity by measles virus.Science 1996;273:228-231.

Karp CL, El-Safi SH, Wynn TA, Satti MMH, Kordofani AM, Hashim FA, Hag-Ali M, Neva FA, Nutman TB, Sacks DL. In vivo cytokine profiles in patients with kala-azar: Marked elevation of both interleukin-10 and interferon-gamma.J Clin Invest 1993;91:1644-1648. PMCID: PMC288142

Professional Organization Memberships

  • American Association of Immunologists
  • American Society of Tropical Medicine and Hygiene
  • American Federation for Clinical Research
  • Infectious Diseases Society of America
  • American Association for the Advancement of Science
  • International Cytokine Society
  • Society for Leukocyte Biology (Councilor)
  • International Endotoxin and Innate Immunity Society
  • American Society for Clinical Investigation

Editorial Activities

  • Section Editor: Journal of Leukocyte Biology
  • Member, Faculty of 1000
  • Editorial Board: Inflammation

Related Areas

This person works in these other areas at Cincinnati Children's Hospital Medical Center: